Phase 3 Momentum: Recent social media chatter highlights the resilience of DFTX shares following positive phase 3 trial outcomes. Observers note the stock's ability to absorb an upsized offering without significant pullback, suggesting sustained investor interest in the company's pipeline progress.
Investor Engagement: Dedicated online forums for DFTX holders have emerged as a focal point, with participants sharing updates and strategies amid the ongoing clinical developments. This reflects broader enthusiasm around the firm's advancements in its therapeutic area.
Note: This discussion summary was generated from an AI condensation of post data.
DFTX Inc. Insider Trading Activity
DFTX Inc. insiders have traded $DFTX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $DFTX stock by insiders over the last 6 months:
- ROBERT BARROW (Chief Executive Officer) has made 0 purchases and 2 sales selling 53,639 shares for an estimated $1,766,476.
- MARK SULLIVAN (Chief Legal Officer) has made 0 purchases and 2 sales selling 23,710 shares for an estimated $783,416.
- DANIEL KARLIN (Chief Medical Officer) has made 0 purchases and 2 sales selling 18,053 shares for an estimated $599,968.
- BRANDI ROBERTS (Chief Financial Officer) sold 3,013 shares for an estimated $135,675
- MATTHEW T. WILEY (Chief Commercial Officer) sold 2,867 shares for an estimated $129,101
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
DFTX Inc. Hedge Fund Activity
We have seen 201 institutional investors add shares of DFTX Inc. stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 8,480,230 shares (+inf%) to their portfolio in Q1 2026, for an estimated $156,163,435
- AVORO CAPITAL ADVISORS LLC added 5,000,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $92,075,000
- DEEP TRACK CAPITAL, LP added 3,000,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $55,245,000
- GEODE CAPITAL MANAGEMENT, LLC added 2,495,399 shares (+inf%) to their portfolio in Q1 2026, for an estimated $45,952,772
- STATE STREET CORP added 2,471,873 shares (+inf%) to their portfolio in Q1 2026, for an estimated $45,519,541
- OCTAGON CAPITAL ADVISORS LP added 2,440,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $44,932,600
- COMMODORE CAPITAL LP added 2,000,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $36,830,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
DFTX Inc. Analyst Ratings
Wall Street analysts have issued reports on $DFTX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 01/30/2026
To track analyst ratings and price targets for DFTX Inc., check out Quiver Quantitative's $DFTX forecast page.
DFTX Inc. Price Targets
Multiple analysts have issued price targets for $DFTX recently. We have seen 12 analysts offer price targets for $DFTX in the last 6 months, with a median target of $54.5.
Here are some recent targets:
- Paul Matteis from Stifel set a target price of $60.0 on 07/08/2026
- Sumant Kulkarni from Canaccord Genuity set a target price of $58.0 on 06/30/2026
- Justin Walsh from Jones Trading set a target price of $74.0 on 06/24/2026
- Christopher Chen from Baird set a target price of $57.0 on 06/23/2026
- Ami Fadia from Needham set a target price of $50.0 on 06/23/2026
- Marc Goodman from Leerink Partners set a target price of $52.0 on 06/22/2026
- Jay Olson from Oppenheimer set a target price of $60.0 on 06/22/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
